Fluent Biosciences Inc, based in Watertown, MA, is revolutionizing single-cell biology by providing scalable and cost-effective solutions for high-quality single-cell RNA sequencing (scRNA-seq). Their PIPseq technology allows for the analysis of up to 2,000 single cells per sample, offering a flexible and complete workflow solution from cell capture to data analysis. With a focus on cancer, immunology, neuroscience, and infectious disease research, Fluent's breakthrough technology eliminates the need for complex instrumentation, allowing researchers to concentrate on advancing their studies without the burden of managing expensive technology.
Fluent's PIPseq scRNA-seq platform has garnered praise from renowned scientists, including Professor Michael Verzi from Rutgers State University, who commends its advantages in experimental flexibility and time-course study design. Dr. Shane Liddelow from NYU Langone highlights the exceptional sequencing quality and its potential impact on neuronal research, while Dr. Zev Gartner from the University of California, San Francisco, emphasizes the platform's ability to meet data quality metrics for clinical specimens. With its simple workflow, high-quality data, and large cell capture capacity, Fluent's technology enables researchers to confidently answer scientific questions and generate new hypotheses for testing.
Generated from the website